PROMO!
First order? Get 10% OFF with this code: 1storder
Epithalon (Epitalon) is a synthetic linear tetrapeptide derived from the short-peptide bioregulator research programme, investigated in preclinical and laboratory models examining cellular aging, telomere-associated biology and gene-expression-related processes.
Four amino acid residues make up the synthetic tetrapeptide Epithalon, also known as Epitalon: Ala-Glu-Asp-Gly (AEDG). It is also known as alanyl-glutamyl-aspartyl-glycine in scientific databases and is categorized as an ultra-short synthetic peptide bioregulator. It differs from bigger peptide hormones and proteins, which usually have more intricate secondary and tertiary architectures, because to its tiny molecular size and linear shape.
Epitalon was developed from research led by Vladimir Khavinson and colleagues into Epithalamin, a peptide-rich extract obtained from bovine pineal tissue. The AEDG sequence was synthesised based on the amino-acid composition of this extract and subsequently investigated as a defined molecular entity. Scientific literature therefore distinguishes synthetic Epitalon from the more chemically heterogeneous Epithalamin preparation.
Epitalon is recognised principally within experimental research concerning short-peptide bioregulation, pineal biology, cellular ageing, gene regulation and telomere-associated molecular biology. Studies have employed in vitro cellular systems, animal models and molecular modelling to investigate its biochemical characteristics and potential molecular interactions. However, several aspects of its mechanism remain unresolved, and the evidence base includes substantial contributions from the original research groups.
Within laboratory settings, synthetic Epitalon provides a chemically defined AEDG research peptide suitable for biochemical, molecular and cell-based investigations. Its short sequence also permits straightforward chemical synthesis and analytical characterisation compared with larger proteins.
Because Epithalon only has four amino acids, it lacks the stable tertiary architecture found in larger proteins. There is no evidence of a permanent conventional secondary structure, and it is a flexible linear molecule. The peptide has an acidic, negatively charged nature around physiological pH due to the many ionizable carboxyl groups provided by its glutamic acid and aspartic acid residues.
Epithalon is strongly hydrophilic rather than lipid-soluble. Its polar and ionisable groups favour interaction with aqueous environments, although practical solubility depends on pH, concentration, counter-ion and formulation.
The basic AEDG molecule contains no disulphide bonds, glycosylation or other complex post-translational modifications.
As an unmodified short linear peptide, Epithalon remains potentially susceptible to chemical and enzymatic degradation in solution. Lyophilisation and controlled laboratory storage are therefore commonly used to maintain sample integrity.
Current laboratory investigations have examined Epithalon (Epitalon; AEDG) as a synthetic tetrapeptide whose molecular mechanism remains under investigation. Unlike classical peptide hormones, Epithalon does not currently have a conclusively identified cognate cell-surface receptor. Published experimental studies have instead focused on potential interactions with telomere-associated processes, gene transcription, chromatin organisation and intracellular regulatory mechanisms.
Telomerase and Telomere-Associated Mechanisms
Investigations of Epithalon in cultured human cells that look at telomerase activity and telomere-associated molecular alterations are described in published experimental studies. The ribonucleoprotein enzyme complex telomerase is in charge of appending repeating nucleotide sequences to the ends of chromosomes. Investigations into whether the peptide interacts directly or indirectly with regulatory systems governing telomerase expression or activity have been spurred by experimental observations involving AEDG. There is currently no known direct molecular binding target inside the telomerase complex.
Gene Expression and Chromatin Regulation
In vitro models have explored whether short peptides such as AEDG can participate in transcriptional regulation. Studies from the peptide-bioregulator literature have examined interactions between short peptides, DNA and chromatin-associated proteins. Molecular modelling and biochemical approaches have also investigated sequence-specific peptide–DNA interactions as a possible mechanism through which transcriptional activity could be modified.
Epigenetic and Nuclear Interactions
Experimental research has examined the broader hypothesis that Epithalon may interact with nuclear regulatory processes, including chromatin accessibility and gene-expression networks. Investigations involving peptide–DNA binding, histone-associated mechanisms and transcriptional responses have contributed to this proposed model. However, these mechanisms remain substantially less characterised than conventional receptor-mediated peptide signalling.
Pineal and Neuroendocrine Molecular Biology
Epithalon has additionally been examined in experimental models of pineal and neuroendocrine regulation, reflecting its historical development from research into pineal-derived peptide preparations. Gene-expression and biochemical studies have investigated molecular pathways associated with pineal cellular regulation.
Overall, Epithalon is best characterised as an investigational peptide bioregulator without a definitively established primary receptor or molecular target. Telomerase-associated regulation, transcriptional mechanisms and peptide–chromatin interactions represent the principal mechanistic areas described in the experimental literature.
The information provided is based on the results of laboratory and preclinical studies of Epithalon and does not prove clinical efficacy, nor does it confirm that the substance is suitable for use in humans. Detailed supporting studies are listed in the references.
One of the most distinctive areas of Epithalon (Epitalon; AEDG) research concerns telomere-associated molecular biology. In vitro investigations have examined telomerase activity, telomere dynamics and cellular replicative processes following AEDG exposure. These experiments have primarily employed cultured human somatic cells and cytogenetic or molecular techniques to characterise telomere-related responses.
Within the more general subject of ultra-short peptide interactions with nucleic acids, epithalon has been studied. AEDG's ability to bind to certain DNA sequences or structures has been investigated thru computational and experimental research. Potential peptide–DNA interactions and their molecular specificity have been characterized using methods such as spectroscopic techniques and molecular modeling.
Epithalon has been studied in relation to the regulation of gene expression. Transcriptional responses after peptide exposure, including genes linked to cellular differentiation and regulatory processes, have been studied in cell-based investigations. This study is a component of a larger examination into the potential interactions between nuclear molecular machinery and short peptide bioregulators.
Another experimental area concerns interactions between short peptides and chromatin-associated structures. Studies within the peptide-bioregulator field have explored relationships between AEDG, histones, chromatin organisation and transcriptional accessibility. These proposed mechanisms remain under investigation and have not established a single definitive nuclear target for Epithalon.
Because Epithalon originated from research involving peptide preparations associated with the pineal gland, experimental studies have examined AEDG in models relevant to pineal and neuroendocrine molecular biology. Investigations have considered gene expression, protein regulation and cellular signalling within pineal-related experimental systems.
Epithalon has also been investigated using experimental models of cellular ageing and replicative senescence. Cultured cells at different stages of their replicative lifespan have been employed to examine chromosome-associated changes, gene-expression patterns and other molecular markers under controlled conditions. This area overlaps substantially with the peptide’s telomere research.
Molecular modelling and biophysical studies have been used to examine the structural behaviour of the AEDG tetrapeptide, including its possible interactions with DNA and other macromolecules. Such research provides a framework for investigating how an extremely short, negatively charged peptide might participate in molecular recognition despite lacking the complex structure of larger peptide hormones.
Analytical verification of Epithalon (Epitalon; AEDG) should establish the identity and purity of the tetrapeptide Ala-Glu-Asp-Gly. Following Solid Phase Peptide Synthesis (SPPS), preparative reverse-phase HPLC may be used to separate the target AEDG peptide from deletion sequences, residual reagents and other synthesis-related impurities.
Analytical RP-HPLC can be used to compare batch consistency and offers a quantitative evaluation of chromatographic purity. LC-MS, or high-resolution mass spectrometry, offers orthogonal identity confirmation by confirming the anticipated molecular species because unadulterated Epithalon has a calculated molecular mass of roughly 390.35 Da. Tandem mass spectrometry (MS/MS) or amino acid analysis can offer sequence or compositional information when further confirmation is needed.
Because the free peptide and salt forms, such Epitalon acetate, have differing chemical compositions, analytical documentation should also differentiate between the two. Peptide identity, sequence, batch number, HPLC purity, observed molecular mass, analytical technique, and relevant specification limitations should all be documented in a batch-specific Certificate of Analysis (CoA).
Epithalon should be stored at 2–8°C in its original, tightly sealed container. Keep the material in a dry environment and protect it from moisture, excessive heat, and direct light.
When handling Epithalon, keep the container closed until the material is needed and limit its exposure to room conditions. Allow a refrigerated vial to reach room temperature before opening to help prevent condensation. Reseal the container after handling and return it to the recommended storage conditions.
Yes. The identical synthetic tetrapeptide, Ala-Glu-Asp-Gly (AEDG), is frequently transliterated as Epithalon or Epitalon. Whilst Epithalon is commonly found in commercial and research settings, Epitalon is especially prevalent in scientific journals and chemical databases.
Epithalon is a synthetic tetrapeptide. It was developed during research into peptide preparations associated with the pineal gland and is chemically defined by the sequence AEDG. It should not be described as an established naturally occurring human peptide, as evidence for endogenous AEDG as an independently biosynthesised peptide remains limited.
While Epithalon is a chemically defined synthetic tetrapeptide that solely contains Ala-Glu-Asp-Gly, Epithalamin is a complicated peptide preparation that was traditionally extracted from cow pineal tissue. Therefore, in scientific documentation, the two names should not be used interchangeably because they refer to different materials.
For Epithalon, no particular high-affinity cell-surface receptor has been definitively identified. Instead, studies have looked into possible nuclear and intracellular mechanisms, such as connections to telomere-related biochemical processes, chromatin control, and gene expression. Its principal molecular target is still unknown.
Telomerase became an important research area after experimental studies examined telomerase activity and telomere dynamics in cultured human cells exposed to AEDG. These findings prompted further investigation of telomere-associated mechanisms, although a direct molecular interaction between Epithalon and the telomerase enzyme has not been conclusively demonstrated.
Yes. Published experimental and computational studies have examined potential interactions between short peptides such as AEDG and DNA or chromatin-associated structures. Molecular modelling, spectroscopic methods and gene-expression experiments have been used to investigate these interactions, although their precise biological significance remains under investigation.
Epithalon has been examined using cultured human cells, primary cell systems, animal models and biochemical or computational models. Experimental work has included cellular senescence and telomere studies, gene-expression investigations, peptide–DNA modelling and research involving pineal-associated molecular biology. The evidence base remains predominantly preclinical.
Epithalon is distinguished primarily by its AEDG tetrapeptide sequence and its historical association with pineal-derived peptide research. Other Khavinson peptides contain different short amino-acid sequences and have been investigated in relation to different tissue systems—for example, Cartalax in cartilage-associated research and Bronchogen in bronchial epithelial research. Despite these distinctions, the proposed tissue-specific mechanisms of this peptide family remain incompletely characterised and require further independent investigation.
Epithalon is provided for laboratory research and scientific investigation only. It is not for human consumption or veterinary use and is not intended for administration. It is not intended to diagnose, treat, cure, or prevent any disease or medical condition. Information on this page is provided for scientific research purposes only.
